경희대학교 의과대학·의학전문대학원

1. Cancer immunology
2. Lung cancer biomarker
3. Immunotherapy and targeted therapy

- 2020.3~ 경희대학교 의과대학 부교수
- 2016.3 ~ 2020.2 경희대학교 의과대학 조교수
- 2012.3 ~ 2013.2 고대안암병원 호흡기내과 임상조교수
- 2010.5 ~ 2012.2 고대안암병원 호흡기내과 임상강사
- 2006.9 ~ 2012.2 고려대학교 의과대학 대학원 내과학 박사
- 2004.9 ~ 2006.8 고려대학교 의과대학 대학원 내과학 석사
- 1996.3 ~ 2002.2 고려대학교 의과대학 졸업(학사)

- 2017 미원임상의학상
- 2018 대한폐암학회 Astrazeneca학술상
- 2021 대한 폐암학회 국제학술대회 Best Presentation Award
- 2021 고의의학상

- 대한 내과학회 교육위원
- 대한 폐암학회 평의원
- 대한 결핵 및 호흡기학회 학술위원
- International Association for the Study of Lung Cancer Member
- American Association of Cancer Research Member

1. High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy, Biomedicines. 2022 Aug 29;10(9):2109
2. Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis, Onco Targets Ther. 2022 Aug 31;15:941-946
3. Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study, Onco Targets Ther. 2021 Oct 21;14:5097-5106
4. Angiogenic activities are increased via upregulation of HIF-1α expression in gefitinib-resistant non-small cell lung carcinoma cells, Oncol Lett. 2021 Sep;22(3):671
5. Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study) Thorac Cancer. 2021 Apr;12(8):1264-1268
6. Clinical application of next-generation sequencing for the management of desmoid tumors: A case report and literature review, Medicine (Baltimore). 2021 Jan 8;100(1):e24238
7. High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy, Onco Targets Ther. 2020 Aug 20;13:8273-8285
8. Diagnostic and Predictive Values of 18 F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma Cancer Manag Res . 2020 Jul 28;12:6453-6465
9. Radiosensitizing effect of combined triptolide and irradiation treatment in lung cancer cell lines Int. J. Radiat. Res, 2019 Oct
10. Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study Onco Targets Ther. 2019 Oct 9;12:8263-8273
11. Clinical utility of a novel natural killer cell activity assay for diagnosing non-small cell lung cancer: a prospective pilot study Onco Targets Ther. 2019 Feb 27;12:1661-1669
12. Hyaluronic acid-induced diffuse alveolar hemorrhage: unknown complication induced by a well-known injectable agent Ann Transl Med. 2019 Jan;7(1):13
13. Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma, Cancer Res Treat. 2019 Jan;51(1):158-168
14. In-Depth Proteomic Analysis of Human Bronchoalveolar Lavage Fluid toward the Biomarker Discovery for Lung Cancers, Proteomics Clin Appl. 2019 Sep;13(5):e1900028
15. Osimertinib for Secondary T790M-Mutation-Positive Squamous Cell Carcinoma Transformation After Afatinib Failure, J Thorac Oncol . 2018 Dec;13(12):e252-e254